Published in Cell on February 23, 2007
Human DNA methylomes at base resolution show widespread epigenomic differences. Nature (2009) 34.27
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Cancer genome landscapes. Science (2013) 25.33
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol (2010) 13.99
Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet (2009) 12.08
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
CpG islands and the regulation of transcription. Genes Dev (2011) 9.50
Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol (2009) 9.29
Initial impact of the sequencing of the human genome. Nature (2011) 9.18
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res (2008) 8.62
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet (2010) 7.39
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol (2010) 5.96
Chromatin organization marks exon-intron structure. Nat Struct Mol Biol (2009) 5.90
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Next-generation genomics: an integrative approach. Nat Rev Genet (2010) 5.88
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci U S A (2011) 5.45
RNA sequence analysis defines Dicer's role in mouse embryonic stem cells. Proc Natl Acad Sci U S A (2007) 5.26
A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics (2012) 4.95
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). Genome Res (2008) 4.84
Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A (2008) 4.75
A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A (2009) 4.72
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
miR-148 targets human DNMT3b protein coding region. RNA (2008) 4.56
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature (2010) 3.90
Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem (2009) 3.88
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Epigenetic regulation of the alternatively activated macrophage phenotype. Blood (2009) 3.76
QUMA: quantification tool for methylation analysis. Nucleic Acids Res (2008) 3.73
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov (2009) 3.50
Large non-coding RNAs: missing links in cancer? Hum Mol Genet (2010) 3.49
Chemical probes for histone-modifying enzymes. Nat Chem Biol (2008) 3.30
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Decoding the epigenetic language of neuronal plasticity. Neuron (2008) 3.23
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
High-throughput bisulfite sequencing in mammalian genomes. Methods (2009) 3.14
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol (2010) 3.02
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol (2011) 3.00
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics (2012) 2.97
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet (2009) 2.90
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta (2007) 2.82
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene (2012) 2.82
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Computational analysis of genome-wide DNA methylation during the differentiation of human embryonic stem cells along the endodermal lineage. Genome Res (2010) 2.61
DNA methylation dynamics in health and disease. Nat Struct Mol Biol (2013) 2.58
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Cell type-specific DNA methylation at intragenic CpG islands in the immune system. Genome Res (2011) 2.51
Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res (2012) 2.45
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene (2011) 2.42
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet (2017) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev (2008) 2.41
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther (2008) 2.38
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol (2014) 2.37
DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet (2009) 2.37
Polycomb group complexes--many combinations, many functions. Trends Cell Biol (2009) 2.36
Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol (2009) 2.34
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev (2007) 2.34
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev (2011) 2.31
PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat Res (2008) 2.31
Global levels of histone modifications predict prognosis in different cancers. Am J Pathol (2009) 2.28
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J Biol Chem (2012) 2.25
DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep (2011) 2.23
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res (2008) 2.22
The hallmarks of cancer. Cell (2000) 113.05
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Inflammation and cancer. Nature (2002) 53.78
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet (2006) 18.08
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev (2006) 14.36
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet (1998) 13.27
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet (2004) 11.31
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature (2006) 10.73
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet (2006) 10.47
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
The epigenetic progenitor origin of human cancer. Nat Rev Genet (2006) 9.65
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature (2006) 7.70
Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev (1999) 7.58
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev (1997) 6.52
Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol (2006) 5.99
Sir2 links chromatin silencing, metabolism, and aging. Genes Dev (2000) 5.95
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Inflammation, a key event in cancer development. Mol Cancer Res (2006) 5.03
Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet (2006) 4.86
Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet (2002) 4.72
Myc influences global chromatin structure. EMBO J (2006) 4.71
The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer (2004) 4.59
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A (2005) 4.57
Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet (2002) 4.36
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet (2005) 3.98
Polycomb, epigenomes, and control of cell identity. Cell (2003) 3.97
Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing. Nat Genet (2002) 3.91
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J Biol Chem (1994) 3.65
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell (1983) 3.56
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
5-methylcytosine, gene regulation, and cancer. Adv Cancer Res (1983) 3.27
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer (2005) 2.89
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res (2005) 2.57
The epigenetic magic of histone lysine methylation. FEBS J (2006) 2.52
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature (1977) 2.44
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol (2006) 2.39
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell (2003) 2.24
Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol (1988) 2.19
Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res (2006) 2.18
Distinct functions are implicated for the GATA-4, -5, and -6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol Cell Biol (1998) 2.17
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
Cancer: crime and punishment. Nature (2005) 1.91
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
Epigenetic silencing mechanisms in budding yeast and fruit fly: different paths, same destinations. Mol Cell (2005) 1.73
Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem (2002) 1.72
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A (1999) 1.55
Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res (2005) 1.54
HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J (2006) 1.41
Synthesis of signals for de novo DNA methylation in Neurospora crassa. Mol Cell Biol (2003) 1.35
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle (2007) 2.55
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol (2004) 2.41
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations. Genome Res (2008) 2.10
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res (2003) 2.03
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res (2007) 1.96
Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res (2004) 1.93
A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res (2012) 1.80
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev (2005) 1.79
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res (2007) 1.77
De novo CpG island methylation in human cancer cells. Cancer Res (2006) 1.73
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med (2008) 1.70
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res (2008) 1.69
Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr (2006) 1.66
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell (2004) 1.65
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res (2008) 1.46
Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res (2004) 1.45
Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res (2002) 1.45
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev (2008) 1.42
Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res (2003) 1.39
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg (2005) 1.37
Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle (2003) 1.36
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis (2008) 1.29
Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res (2009) 1.28
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget (2013) 1.28
MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res (2009) 1.28
Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis (2009) 1.25
Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res (2010) 1.24
CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet (2004) 1.22
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res (2004) 1.20
DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res (2012) 1.17
Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat Rev Genet (2010) 1.13
Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer (2006) 1.12
Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res (2006) 1.12
Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg (2008) 1.12
The methyl-CpG binding protein MBD1 interacts with the p150 subunit of chromatin assembly factor 1. Mol Cell Biol (2003) 1.11
Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. Cancer Res (2010) 1.10
Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res (2006) 1.09
Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res (2013) 1.09
A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res (2008) 1.08
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics (2012) 1.07
Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther (2006) 1.04
Linking cell signaling and the epigenetic machinery. Nat Biotechnol (2010) 1.03
Cancer as a manifestation of aberrant chromatin structure. Cancer J (2007) 1.01
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res (2011) 1.01
CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Clin Cancer Res (2012) 1.00
Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. Oncogene (2005) 0.99
Heterochromatin: stable and unstable invasions at home and abroad. Genes Dev (2003) 0.99
Resistance, epigenetics and the cancer ecosystem. Nat Med (2011) 0.97
Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci (2014) 0.95
Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. Clin Cancer Res (2013) 0.94
A histological survey of green fluorescent protein expression in 'green' mice: implications for stem cell research. Pathology (2007) 0.93